Navigation Links
Dendreon Reports Third Quarter 2007 Financial Results
Date:11/15/2007

lication (BLA) and support the

efficacy claim for PROVENGE.

-- Implemented a committed equity financing facility under which the

Company may sell up to $130 million of its registered common stock to

Azimuth Opportunity, Ltd. over an 18-month period. Dendreon is not

obligated to utilize any of the $130 million facility and remains free

to enter into and consummate other equity and debt financing

transactions.

-- Results from a Phase 1 study of NEUVENGE, an investigational active

cellular immunotherapy, were published in the August 20th issue of the

Journal of Clinical Oncology. The article highlighted the safety

profile, immune response and clinical activity of NEUVENGE in women

with HER2/neu-positive breast cancer who have failed standard therapy.

"We achieved an important milestone this quarter by completing enrollment of our Phase 3 IMPACT trial of PROVENGE, a therapy we believe has the potential to positively impact the lives of many prostate cancer patients who currently have few treatment options," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are grateful to the patients, clinical investigators and nurses who participated in this study. In addition, we would like to thank our vendors and suppliers, in particular the American Red Cross, Progenitor Cell Therapy and the Mayo Clinic, each of which provided high-quality, consistently excellent cell processing and service throughout the trial. We look forward to receiving interim results from this important study next year."

Conference Call Information

Dendreon will host a conference call today at 1:30 p.m. PT, 4:30 p.m. ET. To access the live call, dial 1-877-397-0235 (domestic) or +1 719-325-4876 (international). The call will also be audio webcast and will be available from the Company's website at http://www
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... (PRWEB) July 18, 2014 Reflecting the importance ... past ten years, Connie Rankin, the founder and president ... affiliate, recently introduced a fresh new approach to the ... for a Broker to influence the success of his or ... years. CRES was one of the first in this market ...
(Date:7/18/2014)... Ill. , July 18, 2014 /PRNewswire/ ... infographic highlighting AbbVie and Shire,s complementary fit ... A copy of the infographic ... at:  http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents In ... Code, a copy of this announcement will ...
(Date:7/17/2014)... , July 17, 2014  Vanda Pharmaceuticals Inc. (Vanda) ... on the development and commercialization of products for the ... will release results for the second quarter of 2014 ... The Company will host a conference ... 2014, during which Vanda management will discuss the second ...
(Date:7/17/2014)... devices can only work with a certain incident polarization ... shift the polarization direction of linearly polarized light. A ... out of a birefringent material (such as quartz or ... the thickness of the crystal, the wavelength of light. ... difficulty to integrate on circuits. Then what kind of ...
Breaking Biology Technology:LEED AP Certified ITRA Global / Customized Real Estate Services Introduces New Approach to Its Branding 2NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 2NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 3NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 4NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 5NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 6NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 7Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014 2
... 9, 2011 PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: ... offer, subject to market and other conditions, $135 million aggregate ... under the Company,s shelf registration statement filed with the U.S. ... Company also expects to grant the underwriters a 13-day overallotment ...
... La., May 9, 2011 Following a rigorous ... LLC (AE) have been recommended 1st for state ... (ITRS) component of the Board of Regents Support ... their proposal to develop breakthrough technology for harvesting ...
... Fla., May 9, 2011 Dyadic International, Inc. ... focused on the discovery, development, manufacture and sale ... industrial enzyme and biopharmaceutical industries, today announced that ... and development center in The Netherlands, will be ...
Cached Biology Technology:PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 2PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 3PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 4PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 5LSU-AgCenter and Aquatic Energy Recommended for Clean Technology Grant 2LSU-AgCenter and Aquatic Energy Recommended for Clean Technology Grant 3
(Date:7/21/2014)... hotspots in areas across Riau province on Sunday, July ... following a decline in rainfall. The number of ... what had been reported one day prior, which had ... in six regencies and municipalities, most of which were ... haze it creates could potentially spread via winds to ...
(Date:7/21/2014)... does the word "dog" have meaning? If you say ... you? , Kansas State University philosopher Elliott Wagner aims ... research, which focuses on long-standing philosophical questions about semantic ... philosophers and a mathematician are collaborating to use game ... , "If I order a cappuccino at a coffee ...
(Date:7/21/2014)... Mass. New studies being launched by neurobiologist ... will investigate how estrogens produced in the brains ... songs during a critical window during development. This ... in human children. , In a separate study, ... the idea that estrogens produced in the brain,s ...
Breaking Biology News(10 mins):Philosopher uses game theory to understand how words, actions acquire meaning 2Studying estrogens made by the brain may offer new insights in learning and memory 2Studying estrogens made by the brain may offer new insights in learning and memory 3
... date of the Neanderthal genome, scientists suggest an early ... say the authors, but do not share much else ... this week's issue of Science, also finds no evidence ... study helps to explain the evolutionary relationship between Homo ...
... molecules comprised of chains of repeating structures, are used in ... pipes to reduce flow drag to gene therapy. ... scission, and a new study by the University of Michigan ... previously thought about why polymers break when subjected to strong ...
... The Wistar Institute in Philadelphia and The Vienna Biocenter ... normal repression of the p53 protein, perhaps the single ... humans. , The new molecular pathway described in ... in the progression of many types of cancer. A ...
Cached Biology News:Genetic study of Neanderthal DNA reveals early split between humans and Neanderthals 2Genetic study of Neanderthal DNA reveals early split between humans and Neanderthals 3Scientists find new way to manipulate DNA 2Novel regulatory mechanism identified for key tumor suppressor p53 2Novel regulatory mechanism identified for key tumor suppressor p53 3
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Biology Products: